晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系

doi:10.3969/j.issn.1004-616x.2020.05.004

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (5): 350-354.doi: 10.3969/j.issn.1004-616x.2020.05.004

晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系

刘晓霞¹, 李卫霞¹, 苏镇军², 贾金海³, 段晓辉², 李志加², 贺晓磊², 吕林林², 刘睿², 王云晓²

1. 河北工程大学医学院, 河北邯郸 056038;
2. 河北工程大学附属医院, 河北邯郸 056002;
3. 河北医科大学, 河北石家庄 050017

收稿日期:2020-04-23 修回日期:2020-09-14 出版日期:2020-10-01 发布日期:2020-10-12
通讯作者: 李志加,E-mail:lizjja@163.com E-mail:lizjja@163.com
作者简介:刘晓霞,E-mail:givesunny@163.com。
基金资助:
河北省科技支撑项目（18277703D）；河北省医学适用技术跟踪项目（GZ2020100）

Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum

LIU Xiaoxia¹, LI Weixia¹, SU Zhenjun², JIA Jinhai³, DUAN Xiaohui², LI Zhijia², HE Xiaolei², L Linlin², LIU Rui², WANG Yunxiao²

1. Medical College of Hebei University of Engineering, Handan 056038;
2. Affiliated Hospital of Hebei University of Engineering, Handan 056002;
3. Hebei Medical University, Shijiazhuang 050017, Hebei, China

Received:2020-04-23 Revised:2020-09-14 Online:2020-10-01 Published:2020-10-12

摘要/Abstract

摘要： 目的：探讨晚期非小细胞肺癌（NSCLC）病理特征、放化疗联合治疗疗效、总生存期与患者血清超氧化物歧化酶（SOD）活力的关系。方法：采用基因表达谱数据动态分析数据库（GEPIA）分析不同肿瘤组织SOD的表达情况。收集2018年1—12月河北工程大学附属医院肿瘤科初次确诊的174例晚期NSCLC患者作为研究对象，80例健康者作为对照，放化疗联合治疗前采集患者外周血，分离血清，WST-1法检测血清中SOD活性，根据实体瘤疗效评价标准（RECIST 1.1）评估疗效，追踪随访，分析晚期NSCLC临床病理特征、放化疗联合治疗疗效、总生存期与SOD活力的关系。结果：GEPIA分析显示33类肿瘤中，19类肿瘤组织SOD表达异常，其中肺鳞状细胞癌和肺腺癌组织SOD表达较对照组显著降低（P < 0.05）；WST-1检测结果显示晚期NSCLC患者血清SOD活力显著低于对照组（P < 0.05），不同年龄、性别、病理类型患者血清SOD活力无显著性差异（P > 0.05）；不同吸烟史及病理分级患者血清SOD有显著性差异（P < 0.05），吸烟者血清SOD活力显著低于无吸烟者（P < 0.05），低分化患者血清SOD活力显著低于中、高分化者（P < 0.05）；患者血清SOD活力与放化疗联合治疗疗效呈正相关（r=0.554，P < 0.05），治疗有效患者血清SOD活力显著高于无效患者（P < 0.05），且SOD高活力组患者总生存期显著高于低活力组（P < 0.05）。结论：NSCLC患者血清SOD活性显著降低，且受患者吸烟史、病理分级的影响，可能与放化疗联合治疗疗效和总生存期有关。血清SOD或可作为评估NSCLC临床疗效和判断预后的潜在指标，辅助NSCLC放化疗的疗效判定及预后评估。

关键词: 非小细胞肺癌, 超氧化物歧化酶, 病理特征, 临床疗效, 总生存期

Abstract: OBJECTIVE: To investigate relationships between clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer (NSCLC) with superoxide dismutase (SOD). METHODS: 174 newly diagnosed advanced NSCLC patients in the Department of Oncology,Affiliated Hospital of Hebei University of Engineering were selected in 2018 as the research subjects,and 80 healthy subjects were selected as controls. Peripheral blood and serum samples were collected from patients before they had any therapy. Expression of SOD in different tumors was analyzed via gene expression profiling interactive analysis (GEPIA) and activities of SOD in serum were detected via WST-1. Then,relationships between their expressions,clinicopathological chara cteristics and curative effect of therapy were analyzed. RESULTS: On-line analyses via GEPIA show that the expression of SOD in 19 kinds of tumors was abnormal among 33 kinds of tumors. Expression of SOD in lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) were significantly lower than that in the control group (P < 0.05). The results of WST-1 show that SOD activity in serum of patients was lower than that in the control group (P < 0.05),and there was no difference in serum SOD activity between different ages,genders and pathological patterns of patients (P > 0.05). However,there was significant difference in serum SOD activities between smoking history and pathological grades (P < 0.05). SOD activities were significantly lower in smoking patients compared with non-smoking patients (P < 0.05);and in patients with poor differentiating tumors compared with patients having better differentiating tumors (P < 0.05). SOD activities were positively related to the curative effect of combined therapies (r=0.554,P < 0.05),and it was higher in patients with effective treatment than patients with failed treatment (P < 0.05). Meanwhile,the overall survival in the high activity SOD group was higher than that in the low activity group (P < 0.05). CONCLUSION: SOD activities in serum of patients with advanced NSCLC were significantly decreased. The activities were affected by patients' smoking history,pathological grades,as well as to curative effects of combined therapies and OS. Therefore,SOD can be a potential indicator for evaluating curative effects and prognosis of NSCLC.

Key words: non-small cell lung cancer, superoxide dismutase, clinicopathologic characteristics, curative effect, overall survival

中图分类号:

R734.2

刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.

LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.

[1]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[2]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[3]	赵俊伟, 华辰凤, 尚平平, 谢复炜, 李翔. 亚砷酸As (Ⅲ)诱导人肺癌A549细胞氧化应激反应的实验研究[J]. 癌变·畸变·突变, 2021, 33(1): 28-31.
[4]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[5]	应伟, 王兴远, 江波, 周伟. miR-146a多态性与非小细胞肺癌易感性的研究[J]. 癌变·畸变·突变, 2019, 31(3): 222-226.
[6]	朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀. Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义[J]. 癌变·畸变·突变, 2019, 31(2): 89-95.
[7]	李鸽, 王耀斐, 干娜, 贺琪, 王冠, 韩占锋, 海春旭, 蔺兆星. 小鼠肝再生过程中MnSOD作用的初步研究[J]. 癌变·畸变·突变, 2019, 31(1): 58-63,78.
[8]	吴健彬, 江妹, 王玥, 许晶, 岳文涛, 王子彤. 非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较[J]. 癌变·畸变·突变, 2018, 30(2): 114-119.
[9]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[10]	张静, 滕宇, 赵晓婷, 江妹, 岳文涛. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017, 29(4): 245-250.
[11]	宋杰, 李萍, 于雪新, 冯林, 高燕宁, 肖汀. Syntenin在非小细胞肺癌中的表达及其与患者总生存期的关系[J]. 癌变·畸变·突变, 2017, 29(2): 102-105.
[12]	李超, 倪娟, 徐伟江, 汪旭. miR-22、miR-34a与叶酸介导的一碳代谢在非小细胞肺癌和肝细胞癌中的调控作用[J]. 癌变·畸变·突变, 2016, 28(4): 317-320.
[13]	肖悦, 张建清, 蒋友胜, 周健, 黄海燕, 王晓辉, 李胜浓, 陆少游, 林晓仕. 2,2',4,4'-四溴联苯醚对视黄醛受体和雌激素受体的影响[J]. 癌变·畸变·突变, 2016, 28(3): 161-168.
[14]	翟晓然, 江妹, 赵晓婷, 顾勐, 岳文涛. PFTK1在人非小细胞肺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(3): 231-235.
[15]	吴娟, 杜芸, 王珩, 吴家宁, 赵银环, 王蕊, 张艳, 纪晓坤. 非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义[J]. 癌变·畸变·突变, 2016, 28(1): 27-31.

晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系

Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价